Ridenour v. Boehringer Ingelheim Pharmaceuticals, Inc.

679 F.3d 1062, 2012 WL 1948311, 2012 U.S. App. LEXIS 10919
CourtCourt of Appeals for the Eighth Circuit
DecidedMay 31, 2012
Docket11-2606
StatusPublished
Cited by70 cases

This text of 679 F.3d 1062 (Ridenour v. Boehringer Ingelheim Pharmaceuticals, Inc.) is published on Counsel Stack Legal Research, covering Court of Appeals for the Eighth Circuit primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Ridenour v. Boehringer Ingelheim Pharmaceuticals, Inc., 679 F.3d 1062, 2012 WL 1948311, 2012 U.S. App. LEXIS 10919 (8th Cir. 2012).

Opinion

ROSS, District Judge.

Brian Ridenour filed suit against Boehringer Ingelheim Pharmaceuticals, Inc., Pfizer, Inc., Pharmacia Corporation, and Pharmacia & Upjohn Company, LLC (collectively, “BIP”) alleging tort claims based upon BIP’s marketing and sales of pramiprexole, a drug commonly prescribed as “Mirapex”. Ridenour took Mirapex from 2002 to 2007 to treat symptoms of Restless Leg Syndrome. Ridenour alleges that his use of Mirapex caused compulsive behaviors, such as gambling and hypersexuality. BIP moved for summary judgment, which the district court 2 granted. Ridenour appeals, and we affirm.

*1064 I.

In December 2002, while Ridenour was living in Maryland, his physician, Jamal F. Ali, M.D., began Ridenour on a therapeutic trial of Mirapex. In mid-2003, Ridenour and his wife moved to Las Vegas, Nevada. Ridenour’s new physician, William Gramlich, M.D., continued his Mirapex regimen until October 22, 2007.

Ridenour alleges that from 2003 to 2007, Mirapex caused him to engage in compulsive behaviors, including excessive drinking, sexual thoughts and gambling. In October 2007, Ridenour saw a television advertisement regarding potential side effects of Mirapex. On October 22, 2007, Ridenour mentioned to Dr. Gramlich that he was experiencing compulsive behaviors and “thought” they might be due to Mirapex. Dr. Gramlich’s office note from this visit stated: “Patient in for follow-up. Says he is having side effects from Mirapex. All sorts of compulsive behavior— Not at all clear this is related, but will dc the Mirapex for RLS and switch to re-quip.” Dr. Gramlich testified that his office note accurately reflected his real time communications with Ridenour. Ridenour claims that Dr. Gramlich advised him that there was no link between Mirapex and Ridenour’s compulsive behaviors.

In October or November of 2009, Ridenour saw a television advertisement by a personal injury attorney regarding the connection between Mirapex and compulsive behaviors. After viewing this advertisement, Ridenour contacted law firms regarding his potential claim.

On March 8, 2010, Ridenour filed a lawsuit in the Eastern District of Texas alleging claims for strict liability (design, manufacturing, and warning), breach of express and implied warranties, negligence, negligence per se (violations of 21 U.S.C. §§ 331, 352 and 21 C.F.R. §§ 201.56, 201.57, 202.1), negligent misrepresentation, and violation of the Texas Deceptive Trade Practice Act, Tex. Bus. & Com.Code Ann. §§ 17.01, et seq. The action was transferred to the District of Minnesota on April 6, 2010, as part of the multi-district litigation. Ridenour amended his complaint on March 2, 2011, to eliminate the Texas Deceptive Trade Practices Act claim and add claims for violations of the Maryland Consumer Protection Act, Md.Code Ann., Com. Law §§ 13-101, et seq., and the Nevada Deceptive Trade Practices Act, Nev.Rev.Stat. §§ 598.0903, et seq.

BIP moved for summary judgment before Magistrate Judge Franklin L. Noel, asserting the claims were barred by a two-year statute of limitations for personal injury actions, Nev.Rev.Stat. § 11.190(4)(e). 3 The parties agreed that the applicable statute of limitations period for all Ridenour’s claims, with the exception of his strict liability claim, was two years. In his Report and Recommendation, Magistrate Judge Noel recommended granting BIP’s motion based upon the two-year statute of limitations bar. In his objections to the Report and Recommendation, Ridenour argued, for the first time, that Magistrate Judge Noel “incorrectly applie[d] a two-year limitations period to all of [Ridenour’s] causes of action, while certain of them are actually governed by either a three or four-year statute of limitations.” Ridenour also objected that Magistrate Judge Noel “erroneously applied a two-year limitations period to [Ridenour’s] defective pharmaceutical products liability claim, despite the fact that Nevada law mandates a plaintiff be allowed four years *1065 to file a lawsuit that concerns a defective pharmaceutical products liability claim.”

The district court adopted the magistrate judge’s Report and Recommendation and granted summary judgment. The district court held that Ridenour could not raise new arguments regarding the longer statutes of limitations for the first time in his objections and there was no excuse for the procedural default in this case. Moreover, the district court noted that even if it were to consider Ridenour’s new arguments, the arguments would fail on the merits because Nevada’s two-year statute of limitations applied. 4

Ridenour appeals the adverse grant of summary judgment and argues that the district court’s decision should be reversed and remanded.

II.

We review a district court’s grant of summary judgment de novo, viewing the evidence in the light most favorable to the nonmoving party. Quinn v. St. Louis County, 653 F.3d 745, 750 (8th Cir.2011); Torgerson v. City of Rochester, 643 F.3d 1031, 1042 (8th Cir.2011). Summary judgment is proper if there are no genuine issues of material fact and the moving party is entitled to judgment as a matter of law. Rynders v. Williams, 650 F.3d 1188, 1194 (8th Cir.2011); Taylor v. St. Louis County Bd. of Election Comm’rs, 625 F.3d 1025, 1026 (8th Cir.2010) (per curiam).

In its motion for summary judgment, BIP argued that Ridenour’s causes of action began to accrue in October 2007, and thus the claims were barred by the two-year statute of limitations. In response, Ridenour asserted that his causes of action did not begin to accrue until October or November of 2009, when he saw a television advertisement and researched his claims.

The parties do not dispute that the law of Nevada applies to Ridenour’s claims, with the exception of his claim under the Maryland Consumer Protection Act. The Nevada Supreme Court has held that “[t]he general rule concerning statutes of limitation is that a cause of action accrues when the wrong occurs and a party sustains injuries for which relief could be sought.” Petersen v. Bruen, 106 Nev. 271, 792 P.2d 18, 20 (1990) (citing Nelson v. A.H. Robins Co., 515 F.Supp. 623, 625 (N.D.Cal.1981)); Bemis v. Estate of Bemis, 114 Nev.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Rose v. Bisignano
D. Minnesota, 2025
White Mountain v. Jordan
D. Minnesota, 2025
Schaefer v. Eischen
D. Minnesota, 2025
Smith v. Eischen
D. Minnesota, 2025
ADKINS v. UNION PAC. R.R. CO.
554 P.3d 212 (Nevada Supreme Court, 2024)
Alloway v. Segal
D. Minnesota, 2024
Robinson v. Segal
D. Minnesota, 2023
Keahbone v. Segal
D. Minnesota, 2023
Krasky v. Bolin
D. Minnesota, 2023
Griffis v. Segal
D. Minnesota, 2023
Garcia v. Segal
D. Minnesota, 2023
Stephenson v. Segal
D. Minnesota, 2023
Estabrook v. Segal
D. Minnesota, 2023
Marcks v. Segal
D. Minnesota, 2023
Russell v. Segal
D. Minnesota, 2023
Eviglo v. Eischen
D. Minnesota, 2023
Hanson v. Kijakazi
D. Minnesota, 2023

Cite This Page — Counsel Stack

Bluebook (online)
679 F.3d 1062, 2012 WL 1948311, 2012 U.S. App. LEXIS 10919, Counsel Stack Legal Research, https://law.counselstack.com/opinion/ridenour-v-boehringer-ingelheim-pharmaceuticals-inc-ca8-2012.